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and Los Angeles, CaliforniaOBJECTIVES The purpose of this study was to determine whether the clinical presentation of
lead-associated endocarditis (LAE) is related to the size of lead vegetations and how size is related to
bacteriology and clinical outcomes.
BACKGROUND Cardiac implantable electronic device (CIED) infection may present as either local
pocket infection or bloodstream infection with or without LAE. LAE is associated with signiﬁcant
morbidity and mortality.
METHODS The clinical presentation and course of LAE were evaluated by the MEDIC (Multicenter
Electrophysiologic Device Cohort) registry, an international registry enrolling patients with CIED infection.
Consecutive LAE patients enrolled in the MEDIC registry between January 1, 2009 and December 31,
2012 were analyzed. The clinical features and outcomes of 2 groups of patients were compared based
on the size of the lead vegetation detected by echocardiography (> or <1 cm in diameter).
RESULTS There were 129 patients with LAE enrolled into the MEDIC registry. Of these, 61 patients
had a vegetation <1 cm in diameter (Group I) whereas 68 patients had a vegetation $1 cm in diameter
(Group II). Patients in Group I more often presented with signs of local pocket infection, whereas Group II
patients presented with clinical evidence of systemic infection. Staphylococcus aureus was the organism
most often responsible for LAE, whereas infection with coagulase-negative staphylococci was associated
with larger vegetations. Outcomes were improved among those who underwent complete device
removal. However, major complications were associated with an open surgical approach for device
removal.
CONCLUSIONS The clinical presentation of LAE is inﬂuenced by the size of the lead vegetation.
Prompt recognition and management of LAE depends on obtaining blood cultures and echocardiogra-
phy, including transesophageal echocardiography, in CIED patients who present with either signs of local
pocket or systemic infection. (J Am Coll Cardiol Img 2014;7:541–9) ª 2014 by the American College of
Cardiology Foundation
TA B B R E V I A T I O N S
A N D A C R O N YM S
CIED = cardiac implantable
electronic device
CoNS = coagulase-negative
staphylococci
LAE = lead-associated
endocarditis
TEE = transesophageal
echocardiography
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542he rate of cardiac implantable electronic de-
vice (CIED) infection has increased out of
proportion to the increase in CIED implan-
tations (1–5). This is likely due to an aging
population of CIED recipients with associated
medical comorbidities such as diabetes, heart failure,
and renal sufﬁciency (5). CIED infection is asso-
ciated with substantial morbidity and mortality, as
well as the ﬁnancial costs associated with treatment
(6–9). Prompt recognition and management may
improve outcomes and lower costs. CIED infection
may present as local pocket infection or bloodstreamSee page 550infection with or without lead associated endo-
carditis (LAE) or valve endocarditis (6). Treatment
of CIED infection with LAE includes prompt
removal of all CIED hardware and a prolonged
course of intravenous antibiotics (6,7). There is some
concern about performing percutaneous extractionFrom the *D
Philadelphia,
Minnesota; z
Division of I
Hospital, Bo
North Caroli
lona, Spain;
vision of Car
University of
University of
sociation (to
from Medtro
from Spectra
research gran
disclose.
Manuscript rin patients with large lead vegetations due
to the risk of pulmonary emboli. Moreover,
some clinicians may delay lead removal in
such patients by prescribing a course of
intravenous antibiotics in the hope that the
lead vegetation would decrease in size. The
present study analyzed whether the clinical
presentation, bacteriology, and outcomes of
LAE were inﬂuenced by the size of the lead
vegetation.METHODS
MEDIC (Multicenter Electrophysiologic Device
Infection Cohort) is an international registry con-
sisting of 10 academic medical centers (see the
Online Appendix for a list of enrolling centers) that
prospectively enrolled patients with CIED infec-
tion. The institutional review board at each siteepartment of Medicine, Division of Cardiology, Cardiac Electro
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with a diagnosis of LAE and evidence of a lead
vegetation detected by echocardiography who were
enrolled in MEDIC between January 1, 2009 and
December 31, 2012 were included in this analysis.
Patients were followed for 6 months following
enrollment into MEDIC. Patient demographics,
clinical, and laboratory data at the time of LAE
diagnosis, as well as treatment outcomes were
entered into the MEDIC database.
Deﬁnitions. A diagnosis of LAE was based on the
modiﬁed Duke criteria (7,10). LAE was present if
there was persistent bloodstream infection, docu-
mented by positive blood cultures and the presence
of a lead vegetation documented by echocardiogra-
phy. Patients with an unexplained intracardiac lead
vegetation who presented with local pocket or sys-
temic symptoms but had already been treated with
antibiotics prior to obtaining blood cultures were
also included. Patients with unexplained fever and
persistent unexplained bloodstream infection in the
absence of a documented intracardiac lead vegeta-
tion on echocardiography were not included in this
analysis.
A vegetation was deﬁned as an oscillating intra-
cardiac mass on a pacemaker or ICD lead or cardiac
valve, which was present in >1 echocardiographic
plane. For the purposes of the present analysis,
vegetations that were <1 cm in diameter in a single
plane were characterized as small (Group I) and
vegetations $1 cm were classiﬁed as large (Group
II). Patients with a cardiac valve vegetation in
addition to a lead vegetation were also included in
this analysis.
The time from the most recent CIED procedure
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Table 1. Patient Demographics
Group I
(n [ 61)
Group II
(n [ 68) p Value
Age, yrs 71.3 (61.0, 79.0) 62.7 (52.3, 73.7) 0.017
Male 73.7 66.1 NS
Race, white 68.8 80.8 NS
PPM/ICD 31 (51)/30 (49) 36 (53)/32 (47) NS
Most recent procedure NS
Initial implant 23 (37) 34 (50)
Revision 38 (63) 34 (50)
Total procedures NS
1 29 (47.5) 35 (51.4)
2 23 (37.7) 18 (26.4)
$3 9 (14.7) 15 (22.0)
Months from most
recent procedure
10.7 (1.2, 28.1) 20.2 (4.6, 37.7) NS
Total leads 2.2  0.8 2.3  0.8 NS
EF, % 37.1  16.1 35.7  15.4 NS
Vegetation size, mm 5.1  1.9 19.3  9.0
Values are median (interquartile range), %, n (%), or mean  SD.
EF ¼ ejection fraction; ICD ¼ implantable cardioverter-deﬁbrillator; PPM ¼ permanent
pacemaker; NS ¼ not signiﬁcant.
Table 2. Patient Comorbidities
Group I
(n [ 61)
Group II
(n [ 68) p Value
CAD 37 (60.6) 24 (35.2) 0.002
CABG surgery 16 (26.2) 9 (13.2) NS
Congestive heart failure 42 (68.8) 38 (55.8) NS
Congenital heart disease 5 (8.2) 7 (10.2) NS
Hemodialysis 10 (16.3) 12 (17.6) NS
Prosthetic valve 6 (9.8) 9 (13.2) NS
Anticoagulation 14 (22.9) 22 (32.3) NS
Immunosuppressive use 3 (4.9) 8 (11.7) NS
Steroid use 2 (3.2) 8 (11.7) NS
Implanted central catheter 12 (19.7) 15 (22.0) NS
Vascular graft 11 (18.0) 7 (10.2) NS
Charlson comorbidity index >4 30 (49.1) 24 (35.3) NS
Values are n (%).
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; NS ¼ not signiﬁcant.
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543To assess medical comorbid conditions, we used
the Charlson comorbidity index, which consists of 19
different disease comorbidity categories, weighted
from 1 to 6 based on adjusted relative risk of 1-year
mortality and summed to provide a total score. The
Charlson comorbidity index has previously been
validated as a good predictor of crude mortality (11).
Diagnosis and treatment. Multiple blood cultures
were obtained in each patient. All patients under-
went transthoracic echocardiography. Most patients
also underwent transesophageal echocardiography
(TEE). The diameter of the largest intracardiac
vegetation was recorded by either transthoracic
or transesophageal echocardiography. All patients
underwent an attempt at either percutaneous or
open surgical removal of all hardware. Lead and
pulse generator pocket cultures were obtained.
Following the procedure, the patients received a
prolonged course of intravenous antibiotics based
on published guidelines (7). Reimplantation was
performed at the discretion of the treating physi-
cian. Patients were followed for 6 months from
the date of enrollment. A relapse was deﬁned as
a recurrence of infection with the same organism
based on antimicrobial sensitivity.
Statistical analysis. Summary statistics were gener-
ated for patient demographic information and
baseline clinical presentation to characterize the
study population. This included mean  SD for
continuous variables with nonskewed distribution,
median (interquartile range) for continuous variables
with skewed distribution, and frequency distribution
for categorical variables. A chi-square test or Fisher
exact test was used to compare categorical variables
between early and late LAE patients. Continuous
variables with nonskewed distribution were com-
pared using a 2-sample Student t test, otherwise a
Wilcoxon sum rank test was used. All tests were 2-
sided, and a p value <0.05 was considered statisti-
cally signiﬁcant. Survival curves were constructed
with the Kaplan-Meier method. Differences be-
tween the groups were evaluated using a log-rank
test. To explore the relationship between vegeta-
tion size and 6-month mortality, the local poly-
nomial regression smoothing method was used to
estimate the mortality for each vegetation size and
its 95% conﬁdence interval (12).
RESULTS
Patient demographics. A total of 129 patients with
LAE were prospectively identiﬁed and enrolled into
the MEDIC registry. Group I included 61 patients,
whereas Group II included 68 patients with avegetation $1 cm. The patient demographics are
summarized in Table 1. Patients in Group I were
older than Group II patients (p ¼ 0.017). However,
the groups were similar with respect to sex, race,
type of CIED device, and time from recent surgery.
The most recent CIED procedure in Group I pa-
tients was an initial implant in 23 of 61 (37%) as
compared to 34 of 38 (50%) patients in Group II.
The total number of procedures was similar in both
Table 3.
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544groups. The median time from the most recent
device-related procedure was approximately twice
as long in Group II versus Group I (20.2 vs. 10.7
months), but this did not reach statistical signiﬁcance.
The 2 groups were similar with respect to major
comorbid conditions with the exception of the pres-
ence of coronary artery disease (Table 2). A majority
of Group I patients had coronary artery disease
(60.6%) versus less than one-half among those in
Group II (35.2%, p ¼ 0.002). Major medical
comorbidities were observed in both groups. There
was a high incidence of congestive heart failure
in both groups (68.8% vs. 55.8%, p ¼ NS). A
Charlson comorbidity index of >4 was observed in
49.1% of Group I patients and 35.3% of Group II
patients. The need for hemodialysis or the presence
of an implanted central venous catheter was ob-
served in approximately one-third of the cohort with
LAE. In Group I, 10 of 61 (16.4%) were on he-
modialysis, whereas 12 of 61 (19.7%) had an im-
planted central venous catheter. In Group II, 12 of
68 (17.6%) were on hemodialysis, whereas 15 of 68
(22%) had an implanted central venous catheter.
The presenting symptoms of LAE differed based
on the size of the lead vegetation (Table 3). Patients
with smaller vegetations (Group I) more often pres-
ented with local signs of infection such as pocket
erythema, pain, swelling, warmth, or drainage.Presenting Symptoms
Group I
(n [ 61)
Group II
(n [ 68) p Value
ocal infection
a 26 (42.6) 11 (16.1) <0.001
25 (40.9) 10 (14.7) <0.001
g 16 (26.2) 5 (7.3) <0.001
19 (31.1) 5 (7.3) <0.001
12 (19.6) 9 (13.2) NS
e 15 (24.5) 8 (11.7) 0.026
ystemic infection
38C 38 (62.3) 53 (77.9) 0.028
weats 31 (50.8) 51 (75.0) 0.002
14 (22.9) 35 (51.4) <0.001
ytosis 22 (36.0) 38 (55.8) 0.016
l signs
9 (14.7) 10 (14.7) NS
of valve involvement
cuspid valve regurgitation 2 (3.2) 15 (22.0) 0.001
egetation 12 (19.6) 15 (22.0) NS
n (%).
signiﬁcant.These signs were observed in a minority of patients
with larger vegetations (Group II). In contrast,
Group II patients with LAE and larger vegetations
more frequently presented with signs of systemic
infection such as fever, chills, signs of sepsis, and
leukocytosis. Peripheral emboli were seen with
similar frequency in both groups (14.7% vs. 14.7%,
p ¼ NS). Concomitant valve vegetations were
equally observed in both groups (19.6% vs. 22.0%,
p ¼ NS) as well. In Group I patients, a vegetation
was seen on the aortic valve in 1 (1.6%), the mitral
valve in 3 (4.9%), and tricuspid valve in 8 (13.1%).
In contrast, in Group II patients, a vegetation was
seen on the aortic valve in 3 (4.4%), the mitral valve
in 3 (4.4%), and the tricuspid valve in 9 (13.2%). Of
note, new tricuspid valve regurgitation was more
commonly observed in patients with larger vegeta-
tions (22.0% vs. 3.2%, p ¼ 0.001).
TEE was the imaging modality used to assess
a vegetation in most patients (Fig. 1). A vegetationFigure 1. Vegetations Detected by Echocardiography
in Patients With LAE
(A) A small 0.7-cm vegetation (arrow) was detected on the right
atrial (RA) lead in a Group I patient with S. aureus lead-associated
endocarditis. (B) A large 2.4-cm vegetation (arrow) was detected
on the proximal portion of the right ventricular (RV) lead as it
passed through the RA in a Group II patient with gram-negative
lead-associated endocarditis. LA ¼ left atrium; LAE ¼ lead-
associated endocarditis.
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545was assessed by transthoracic echocardiography in
only 6 of 61 (9.8%) Group I patients and 5 of 68
(7.3%) Group II patients (p ¼ NS). It is assumed
that all patients had a transthoracic echocardiogram
prior to a TEE. Therefore, although the median
lead vegetation diameter was 17.5 mm in Group II
patients, TEE was the imaging modality for deﬁn-
ing the size of a vegetation in most cases.
Bacteriology. Blood cultures were positive in 39 of
61 (65%) Group I patients and 55 of 68 (80%)
Group II patients (p ¼ 0.042). The number of
patients who received antibiotics prior to obtaining
blood cultures at a MEDIC site is not known.
Staphylococci, the most frequent pathogens associ-
ated with LAE, were cultured in 35 of 61 (55%)
Group I patients and 43 of 68 (63%) patients in
Group II (p ¼ 0.002) (Fig. 2). The distribution
of S. aureus and coagulase-negative staphylococcal
infection varied between the groups. The coagulase-
negative staphylococci (CoNS) cultured refer to a
broad group of species that generally inhabit the
skin. These include organisms such as S. epidermidis,
S. hominis, and S. lugdunensis. S. aureus was re-
sponsible for LAE in 27 of 61 (44.2%) Group I
cases, whereas CoNS were responsible for only 6
of 61 (9.8%) Group I cases. In contrast, in Group II
patients with larger vegetations, CoNS were
responsible for 21 of 68 (30.8%) cases of LAE,
whereas S. aureus infection was present in 22 of 68
(32.2%) patients. Methicillin resistance was com-
monly observed with S. aureus LAE. MethicillinFigure 2. Microbiology of LAE
Staphylococci were the most frequent pathogens associated with
lead-associated endocarditis (LAE). S. aureus was the predominant
pathogen in Group I patients with LAE, whereas in Group II pa-
tients with larger vegetations, coagulase-negative staphylococci
(CoNS) and S. aureus were equally observed. CoNS infection was
seen in a minority of Group I patients. Gram POS ¼ gram-positive;
Gram NEG ¼ gram-negative; MRSA ¼ methicillin-resistant
S. aureus; MSSA ¼ methicillin-sensitive S. aureus.resistance was present in 14 of 27 (52%) Group I
patients and 7 of 22 (32%) Group II patients. Other
gram-positive organisms were cultured in 9 (14.7%)
Group I patients and 8 (11.7%) Group II patients.
The gram-positive organisms included viridans
group streptococci (Group I ¼ 0, Group II ¼ 1
[1.4%]), Enterococcus (Group I ¼ 5 [8.6%], Group
II ¼ 6 [8.8%]), Propionibacterium (Group I ¼ 2
[3.2%], Group II ¼ 0), and Group B beta hemolytic
strep (Group I ¼ 2 [3.2%], Group II ¼ 1 [1.4%]).
Gram-negative bacilli were only cultured in Group I
patients (n ¼ 3 [4.9%]). These included Klebsiella
(n ¼ 2 [3.2%]) and Serratia (n ¼ 1 [1.5%]). No
organism was cultured in 9 of 61 Group I patients
(14.7%) and only 2 of 68 Group II patients (3%).
Many patients were likely on intravenous antibiotics
at the time of evaluation at a MEDIC site, which
probably accounts for the observed rate of negative
cultures.
Outcome. The entire CIED system was removed in
all Group I patients and in 65 of 68 (96%) Group II
patients. The system was removed at the time of
initial presentation in 37 of 61 (60.6%) Group I
patients and 55 of 68 (80.8%) Group II patients. A
laser sheath was used in 62.2% of Group I patients
and 49.0% of the Group II patients. An operative
thoracotomy/sternotomy was performed in 4 (6.5%)
Group I patients and 13 (19.0%) Group II patients.
The 17 patients who underwent open thoracotomy/
sternotomy had larger vegetations than did the 112
patients who had their CIED system removed using
a percutaneous approach (19.8  13.7 mm vs. 11.2
 8.5 mm, p < 0.001).
The indications for an open thoracotomy/
sternotomy in the 4 Group I patients were: cross-
over from percutaneous extraction in 1 (vascular
trauma); need for epicardial leads in 1; and the need
for concomitant valve surgery in 2. Therefore, only 3
Group I patients went directly for surgical extrac-
tion. In the 13 Group II patients who underwent
an open thoracotomy/sternotomy, the indications
included: crossover from percutaneous extraction in
3 (vascular trauma in 1 and failed extraction in 2);
need for epicardial leads in 1; concomitant valve
surgery in 2; and reported size of the vegetation
(median ¼ 2.6 cm, range 2.5 to 4.1 cm) in 6; and
unknown in 1. Therefore, 10 Group II patients
went directly to the operating room for open ster-
notomy/thoracotomy.
Major procedure-related complications, as a
result of CIED removal, occurred in 1 (1.6%)
Group I patient versus 7 (12.1%, p ¼ 0.09) Group
II patients. The complication in the Group I pa-
tient was a respiratory arrest or anesthesia-related
Figure 3.
There wa
larger veg
Figure 4. Relationship Between Vegetation Size
and 6-Month Mortality
The dots represent the observed 6-month patient survival (alive or
dead), whereas the solid line is the estimated mortality based on
the local polynomial regression smoothing method. The dotted
lines give the 95% conﬁdence interval.
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546complication that lead to prolonged hospitalization.
There were no other vascular complications in this
group of patients. In addition, there were no com-
plications in the 3 Group I patients who proceeded
directly to open thoracotomy/sternotomy. In con-
trast, major complications were observed in 2 of 10
Group II patients who went directly to an open
thoracotomy/sternotomy and 5 of 58 Group II pa-
tients who had attempted percutaneous removal
of their CIED system. The major complications
associated with direct open sternotomy/thoracot-
omy included respiratory failure in 1 and remote
infection in 1 patient. The 5 major complications
associated with percutaneous removal included a
vascular tear in 2 (1 requiring operative repair),
stroke in 1, and pulmonary embolism in 2 patients.
There were no operative deaths.
Patients were treated with a prolonged course of
intravenous antibiotics. The duration of antibiotics
was longer in Group II patients than in Group I
patients (p < 0.01). A new device was implanted in
50% of patients and did not differ across the groups
(p ¼ 0.925).
In-hospital mortality was 9.8% (6 of 61) in
Group I and 11.7% (8 of 68) in Group II (p ¼ NS).
Complete 6-month follow-up data was available for
124 of 129 patients with LAE. Two patients had
relapse or suspected recurrent device infection, 1 in
each group. Six-month mortality was 10.1% in
Group I and 18.4% in Group II (p ¼ NS) (Fig. 3).
Six-month mortality was also evaluated as a func-
tion of vegetation size. Mortality signiﬁcantly in-
creased as a function of vegetation size (Fig. 4).DISCUSS ION
An analysis of this large cohort of patients with
LAE provides the following insights: 1) the clinical6-Month Survival in Patients With LAE
s a trend toward worsened survival in Group II patients with
etations. LAE ¼ lead-associated endocarditis.presentation of LAE differs based on vegetation
size; 2) patients with LAE who present with local
pocket infection usually have smaller vegetations,
whereas those presenting with systemic manifesta-
tions of infection tend to have larger vegetations;
3) whereas S. aureus is the predominant pathogen
associated with LAE, patients with LAE due to
coagulase-negative staphylococci tend to have larger
vegetations; and 4) major complications are more
common in patients with larger vegetations, prin-
cipally due to the increased use of open surgical
intervention in this group.
Clinical presentation of LAE. CIED infection may
present as local pocket infection or systemic blood-
stream infection associated with LAE (7,13–15).
LAE represents 19% to 23% of total CIED infec-
tion and may present many months after the most
recent CIED procedure (16–18). Patients with
LAE may present with signs of local pocket in-
ﬂammation and bacteremia or as a systemic illness
with fever, chills, sweats, and signs of sepsis. Our
previous analysis of 145 patients with LAE showed
that the time from the most recent CIED procedure
inﬂuenced the clinical presentation (16). Patients
who developed LAE soon after a CIED procedure
were more likely to present with local infection. In
contrast, those with LAE that occurred more than
6 months following a CIED procedure were more
likely to present with signs of systemic infection.
This is likely due to the fact that early LAE is
usually due to progression of pulse generator infec-
tion that involves the leads, whereas late LAE is
frequently due to hematogenous seeding from
remote sources of infection such as dialysis
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547catheters, central venous catheters, arteriovenous
ﬁstulae, or peripheral abscesses.
In this study, we analyzed the importance of
vegetation size on the clinical presentation and
outcome of LAE in a large, prospective cohort of
patients. Patients were categorized in 2 groups that
were based on the size of the largest lead vegeta-
tion seen on echocardiography. Demographics and
medical comorbidities of patients with vegetations
$1 cm or <1 cm were similar except that those with
smaller vegetations (Group I) were older and had a
higher incidence of coronary artery disease. Group I
patients were more likely to present with signs of
local infection, whereas Group II patients more
frequently presented with systemic symptoms or
sepsis. Emboli or concomitant valve involvement
were equally prevalent in both groups, though, not
surprisingly, Group II patients had more evidence
of new tricuspid valve regurgitation.
The diagnosis of LAE relies on the detection of a
lead vegetation on echocardiography as well as the
documentation of bloodstream infection (6,7,19).
Importantly, patients with LAE may present with
signs of pocket infection without systemic mani-
festation of infection. Therefore, it is critical that
blood cultures be obtained in all patients with sus-
pected CIED infection at initial presentation,
before starting empiric antibiotics, regardless of the
clinical presentation. TEE is most often required to
detect lead vegetations (7). Consequently, the im-
portance of performing a TEE in any CIED patient
with unexplained fever or bacteremia, especially
when due to a staphylococcal species, cannot be
overemphasized.
LAE may be present without a vegetation
detected by standard imaging. In our previous study
of 145 CIED patients with LAE based on modiﬁed
Duke criteria, 24% had no evidence of a lead veg-
etation by either transthoracic echocardiography or
TEE (16). The present study only analyzed patients
who had a vegetation detected on echocardiography.
Recently, Narducci et al. (20) found that intracar-
diac echocardiography was more sensitive than
TEE in identifying LAE. This suggests that in-
tracardiac echocardiography may be an additional
modality to detect lead vegetations in patients with a
negative TEE but a high index of suspicion for
underlying endocarditis.
Detection of lead masses or vegetations. Lead
masses or vegetations may be found in patients who
do not have infection. Novak et al. (21) performed
a special autopsy in 78 patients (pacemaker ¼ 67,
implantable cardioverter-deﬁbrillator ¼ 11) with
various modes of death to evaluate the intracardiacleads in CIED patients. Thrombi along the lead were
present in 26 (33%) patients. Previous investigators
have found incidental lead masses in 5% to 10% of
patients without a suspicion for LAE who undergo
TEE (22,23). In addition, mobile thrombi have
been detected on CIED leads in 30% of patients
undergoing intracardiac echocardiography as part of
a cardiac ablation procedure (24). The morphology of
these incidental masses has not been systematically
compared with those in infected patients. Therefore,
the characteristics of a pathologic mass or vegetation
remain to be deﬁned. For these reasons, masses or
vegetations on intracardiac leads must be interpreted
within the clinical context as we suggest in our
deﬁnition of lead-associated endocarditis.
Bacteriology of LAE. Staphylococcal species are
the predominant organisms responsible for CIED
infection and LAE (6,13,25). Previous studies have
shown that S. aureus is responsible for approxi-
mately two-thirds of cases. However, more indolent
organisms such as the coagulase-negative staphylo-
cocci are important pathogens, particularly in late-
onset LAE (16,26). Our previous investigation of
LAE showed that CoNS was responsible for
LAE in 7 of 43 (16.3%) cases presenting <6
months from the most recent CIED procedure but
25 of 102 (24.5%) cases of late-onset LAE (16). Le
et al. (26) highlighted the distinct clinical features
of S. aureus and CoNS CIED infection. They ob-
served that pocket infection due to S. aureus tended
to occur early after a CIED procedure, whereas
systemic infection tended to present later. In con-
trast, with CoNS infection, the timing of the CIED
procedure did not impact whether patients devel-
oped local infection versus systemic infection.
Patients with endovascular CoNS were more likely
to have had previous CIED infection, more CIED
procedures, and more abandoned leads. The asso-
ciation between S. aureus bacteremia and LAE is
well known (27,28). However, Madhavan et al. (29)
found that the underlying CIED infection was also
present in 36% of patients with CoNS bacteremia
and 20% in those with non–gram-positive coccal
bacteremia. These data and ﬁndings from our cur-
rent analysis reinforce the importance of obtaining
blood cultures and TEE in patients with a pre-
existing CIED who present with systemic illness
including fever, chills, or signs of sepsis.
Impact of vegetations on the clinical presentation
and course of LAE. We found that patients pre-
senting local pocket infection had smaller vegeta-
tions, whereas larger vegetations were more
commonly associated with signs of systemic illness.
Larger vegetations may be the result of indolent
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548infection or a delay in the diagnosis of LAE, allowing
existing vegetations to enlarge. An analysis of the
MEDIC data does not allow us to make this
distinction because we are unable to measure the time
from onset of illness to diagnosis. However, in our
series, larger vegetations were more commonly asso-
ciated with CoNS infection. It has previously been
noted that CoNS infection does not present with
systemic illness as often as it does with S. aureus
infection (26). This suggests that CoNS infection is
more indolent with slower disease progression, thus
presenting with larger vegetation size. These data also
suggest that management of potential pocket infec-
tion is crucial because a delay in deﬁnitive treatment
may lead to a more serious situation with larger veg-
etations and increased morbidity and mortality.
American Heart Association and Heart Rhythm
Society guidelines recommend complete device
removal with a prolonged course of antibiotics in any
patient with CIED infection (7). Lead removal can
be accomplished in most cases using percutaneous
techniques (30,31). Clinically signiﬁcant pulmonary
emboli secondary to percutaneous extraction are rare.
This is even true for patients with large vegetations
seen on echocardiography (30). An open surgical
approach is usually reserved for those patients with
concomitant valvular endocarditis or those with
extremely large vegetations, generally >3 cm (7,31).
In our study cohort, the CIED system was suc-
cessfully removed in all but 3 of 129 patients, all of
whom had large vegetations. A direct open surgical
approach was used in a minority of our patients: 3 in
Group I and 10 in Group II. Four additional pa-
tients (1 in Group I and 3 in Group II) went for an
open surgical approach either as the result of a failed
percutaneous extraction or a vascular tear related to
the procedure. Complications of lead removal were
more common in those with larger vegetations,
driven by complications in those requiring an open
surgical approach. Therefore, earlier diagnosis of
LAE when vegetations are relatively smaller could
help avoid the need for open surgery and reduce the
complications associated with this approach.
Study limitations. The decision to use 1 cm as the
vegetation size separating the 2 groups was arbitrary
but represented the approximate median vegetationsize of the cohort. The present study was designed to
answer the question of whether the clinical presen-
tation and course of LAE was inﬂuenced by vege-
tation size. Unfortunately, it will not resolve the
debate regarding which patients should undergo
surgical extraction. It was not designed to answer the
question of the safety of percutaneous extraction of
large vegetations because only 12 of 129 patients had
a vegetation>2.5 cm. In addition, this study was not
able to systematically review all of the cardiac im-
aging performed on these patients. Therefore, we are
unable to directly compare the sensitivity of trans-
thoracic versus transesophageal echocardiography in
detecting and measuring an intracardiac vegetation.
However, in our cohort, a vegetation was measured
by transthoracic echocardiography in only 9.8% of
Group I and 7.3% of Group II patients. Although
the measurement of the largest diameter of a vege-
tation was consistent, we are not able to characterize
vegetation morphology, location, or characteristics,
such as calciﬁcation or mobility. Data was obtained
from MEDIC sites using multiple echocardiog-
raphers. Therefore, we are unable to make any
conclusions regarding vegetation morphology and
clinical outcomes. Finally, the patient population
studied in MEDIC reﬂects those referred to aca-
demic medical centers for treatment and may not be
representative of all patients with LAE.CONCLUS IONS
Data from our large prospective cohort of patients
with LAE and intracardiac vegetations suggest
that the clinical presentation and clinical course of
patients with CIED infection are inﬂuenced by
vegetation size. Prompt diagnosis of LAE may
impact clinical outcome as complications, including
the need for an open surgical approach, are more
common in those with large vegetations.
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